Could non steroidal anti-inflammatory drugs be used to potentiate L.M.W.H. activity in thrombosis? (Part II)

Thromb Res. 1992 May 15;66(4):445-9. doi: 10.1016/0049-3848(92)90293-j.


Thromboembolic diseases are one of the main cause of mortality. Heparin fractions obtained by chemical or enzymatical depolymerization of unfractionated heparin are now widely used in the prevention of those illness. However, curative dosages have bad side effects which could be avoid by the potentiation of the antithrombotic efficacy of non-active dosages. A previous study (4) has shown that a non-steroidal anti-inflammatory (NSAI) drug like Phenylbutazone could favour the antithrombotic efficacy of Fraxiparine at a very low dose. The aim of this study was then to determine if other NSAI elements could present the same or better proactive effects.

MeSH terms

  • Animals
  • Anti-Inflammatory Agents, Non-Steroidal / pharmacology*
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
  • Blood Coagulation Tests
  • Double-Blind Method
  • Drug Synergism
  • Fibrinolysis / drug effects
  • Hemostasis / drug effects
  • Heparin, Low-Molecular-Weight / pharmacology*
  • Heparin, Low-Molecular-Weight / therapeutic use
  • Male
  • Rats
  • Rats, Wistar
  • Thrombophlebitis / drug therapy*
  • Vena Cava, Inferior*


  • Anti-Inflammatory Agents, Non-Steroidal
  • Heparin, Low-Molecular-Weight